Atai Life Sciences announces FDA Investigational New Drug (IND) Clearance for PCN-101 R-ketamine Program

Enables expansion of PCN-101 clinical development to the U.S. • atai plans to initiate clinical drug-drug interaction (DDI) study in early 2022 to assess pharmacokinetics of PCN-101 when used concurrently with other drugs • DDI trial will complement existing Phase 2a trial in treatment-resistant depression (TRD) recently initiated in Europe NEW YORK, Jan. 12, 2022 (GLOBE NEWSWIRE) — atai Life...

Source

Article Link: atai Life Sciences announces FDA Investigational New Drug (IND) Clearance for PCN-101 R-ketamine Program - Psilocybin Alpha